Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of autologous Activated T Lymphocytes ATL as a preventive immunotherapy in patients with hepatocellular carcinoma HCC who have undergone curative treatment. This Phase II, open-label, single-arm, multicenter study focuses on patients with Stage I, II, or IIIa HCC, reflecting a previous studys patient distribution. The goal is to assess relapse-free survival over 12 months following ATL administration. Eligible patients will receive ten intravenous infusions of ATL at specific weeks 1, 2, 3, 4, 6, 8, 10, 14, 18, and 22. Before treatment, peripheral blood is collected at least 28 days prior to manufacturing the ATL agent. The first three patients receive the ATL doses in a staggered manner to monitor safety. A Data and Safety Monitoring Board will review safety data after 10% of participants complete four ATL infusions to decide on study continuation or adjustments. Participants will be closely monitored through various assessments including blood tests, imaging MRI or CT scans, and evaluations of performance status and quality of life using standardized questionnaires. Safety measures include monitoring adverse events, vital signs, lab values, ECG results, and physical exams over a period of up to 76 weeks. The primary outcome is relapse-free survival at 12 months post-treatment initiation, with additional secondary outcomes assessing overall survival, biomarkers, and functional status changes.
Actively Recruiting
Researchers are studying different methods of managing pain after caesarean section, a common surgery often causing severe postoperative pain. This observational, prospective cohort study aims to understand how well different analgesic methods work, including their impact on pain intensity, recovery, and postpartum depression. The study focuses on women aged 20 to 40 undergoing elective caesarean section with spinal anesthesia. Participants will be grouped based on the pain management methods they receive one group receives a combination of intravenous patient-controlled analgesia IV-PCA and a single intramuscular dose of dinalbuphine sebacate NALDEBAIN, while the other group receives IV-PCA alone. IV-PCA typically uses morphine delivered by a device installed after delivery and removed within three days. Dinalbuphine sebacate is a long-acting prodrug given once after delivery to help alleviate pain. During the study, researchers will collect data from medical records, questionnaires, patient diaries, and phone visits. They will assess pain intensity within five days after delivery, analgesic use, complications, recovery details like ambulation and gastrointestinal function, breastfeeding, and postpartum depression up to three months after delivery. Participants satisfaction and chronic pain levels will also be evaluated. This comprehensive monitoring aims to provide detailed insights into postoperative pain management and recovery outcomes.